Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Muscular Dystrophies: early-phase trial registry

5 of 12 indexed Muscular Dystrophies trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 5 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Muscular Dystrophies: 12 US clinical trials tracked, 5 recruiting.

Muscular Dystrophies is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Leigh R. Hochberg, MD, PhD., running 2 of these trials.

Enrollment posture brief

Registry condition muscular-dystrophies

OPEN 5 | RECR 42% | LATE 1 | EARLY 2 | RANK #1429 | SPON 2

Nearest open-share peer: Adiposity (42% recruiting · 12 trials)

Muscular Dystrophies (this)42%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Muscular Dystrophies

Muscular Dystrophies lists 5 open slots (42% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Muscular Dystrophies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Muscular Dystrophies is recruiting below its size-band peers.

    5 of 12 indexed trials (41.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Muscular Dystrophies research.

    Leigh R. Hochberg, MD, PhD. accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Most Muscular Dystrophies trials plan to enrol fewer than 100 people.

    Median target enrolment is 51 among the 12 trials that report a genuine target (sentinel values excluded). 8 of those (66.7%) plan for fewer than 100 participants.

  4. Muscular Dystrophies research is mostly interventional.

    9 interventional and 3 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 31

Open and recent trials

12 total, page 1 of 1

RECRUITING 9,300 participants

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

National Institute of Neurological Disorders and Stroke (NINDS)

NCT01568658

RECRUITING Phase 2 51 participants

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Satellos Bioscience

NCT07287189

RECRUITING NA 3 participants

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

Leigh R. Hochberg, MD, PhD.

NCT05724173

RECRUITING NA 3 participants

ECoG BMI for Motor and Speech Control

Karunesh Ganguly

NCT03698149

RECRUITING NA 2 participants

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)

Leigh R. Hochberg, MD, PhD.

NCT06094205

ACTIVE NOT RECRUITING Phase 3 106 participants

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Capricor

NCT05126758

ACTIVE NOT RECRUITING 80 participants

Defining Endpoints in Becker Muscular Dystrophy

Virginia Commonwealth University

NCT05257473

ACTIVE NOT RECRUITING NA 20 participants

NuroSleeve Powered Brace & Stimulation System to Restore Arm Function

Thomas Jefferson University

NCT04798378

ACTIVE NOT RECRUITING NA 6 participants

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Synchron Medical

NCT05035823

COMPLETED NA 177 participants

Power Over Pain (POP) Study

University of Washington

NCT01800604

COMPLETED 101 participants

Biomarker Development in LGMD2i

ML Bio Solutions

NCT04202627

COMPLETED Phase 2 37 participants

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

Avidity Biosciences

NCT05479981

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Muscular Dystrophies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BrainGate Neural Interface System Device
2 trials
Placebo Drug
2 trials
AOC 1001 Drug
1 trials
Pain Self-Management Intervention #4 Behavioral
1 trials
Pain Self-Management Intervention #3 Behavioral
1 trials
Pain Self-Management Intervention #2 Behavioral
1 trials
Pain Self-Management Intervention #1 Behavioral
1 trials
Deramiocel (CAP-1002) Biological
1 trials

US sites by state

Facility locations filed on Muscular Dystrophies trials. A trial with sites in several states counts in each.

California 8 trials
Virginia 5 trials
Ohio 5 trials
Colorado 5 trials
Missouri 4 trials
Maryland 4 trials
Kansas 4 trials
Washington 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Muscular Dystrophies page

12 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Muscular Dystrophies condition card totals 12 registered trials; most-linked intervention BrainGate Neural Interface System; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.